Uncategorized
IOP spikes after dexamethasone intravitreal implant manageable
SAN DIEGO — Repeat injections of dexamethasone intravitreal implant have no cumulative effect on IOP, and the rate of high IOP spikes is low, according to a speaker here. The MEAD study, which was the basis for the recent U.S. Food and Drug Administration approval of Ozurdex (dexamethasone intravitreal implant, Allergan) for treatment of diabetic macular edema (DME) in patients who are pseudophakic or scheduled for cataract surgery, also demonstrated the adverse effect of increased IOP in 36% of treated patients.